Corporate Governance

Board of Directors

Ms. Council has served as Chair of the Board since May 2025. She is the Chief Executive Officer of Emerald One, LLC, a consulting company focused on helping business and technology organizations transform through digital change. She was the National Managing Principal, Enterprise Technology Strategy & Innovation for Grant Thornton LLP from December 2017 to November 2019. She served as the Senior Vice President and General Manager for MITRE Corporation from 2017 to 2018 and as the Assistant Secretary for Information & Technology and Chief Information Officer for the United States Department of Veteran Affairs from 2015 to 2017. Ms. Council was the Chief Executive Officer of Council Advisory Services, LLC from 2012 to 2015 and served as the Corporate Vice President and Global Chief Information Officer for Johnson & Johnson from 2006 to 2011. Before that, she served in several roles of increasing responsibility at DELL, Inc., most recently as the Global Vice President, Information Technology, Global Business Solutions, and Development Services. Ms. Council also serves on the Board of Directors of Concentrix (Nasdaq: CNXC), where she serves on the Audit and Compensation Committees, as well as the Board of Thomson Reuters (NYSE: TRI), where she serves on the Audit and Risk Committees. Ms. Council received her Master of Business Administration from Illinois State University and her Bachelor of Business Administration from Western Illinois University. She also holds an honorary Doctorate of Business Administration from Drexel University. Ms. Council also serves on the global Board of Girl Up, a UN Foundation Organization. The Board of Directors has determined that Ms. Council is independent within the meaning of the rules of the New York Stock Exchange.

Ms. Council’s qualifications for appointment to CONMED’s Board include her extensive experience as a global operations and information technology executive with budgets ranging up to $4.5 billion per year. The Board strongly believes that the Board and Company benefit from the perspective that Ms. Council brings from her business experience. She has the ability and willingness to serve on the Board, and the correct fit to work in a collegial manner with the other directors.

Mr. Beyer was promoted to the role of President and Chief Executive Officer and appointed to the Board of Directors in January 2025. Prior to this, Mr. Beyer was the Company’s Chief Operating Officer from April 2024 to December 2024, the President of International and Global Orthopedics from October 2020 to April 2024, and President of CONMED International from December 2014 to October 2020. Prior to joining the Company, Mr. Beyer served as Chief Executive Officer of ICNet, a privately held infectious control software company, from 2010 until the company was sold in 2014. Prior to this, Mr. Beyer spent 21 years at Stryker Corporation (NYSE: SYK) where he led Stryker Europe from 2005 to 2009, Stryker UK, South Africa and Ireland from 2002 to 2005, and Stryker Medical from 1999 to 2002. Mr. Beyer is on the Board of Bioventus (NASDAQ: BVS) previously Misonix, where he is a member of the Audit Committee. Mr. Beyer graduated from Kalamazoo College with a Bachelor of Arts in Economics and Western Michigan University with a Master of Business Administration in Finance. He also completed Harvard Business School’s Advanced Management Program.

Mr. Beyer’s qualifications for election to CONMED’s Board include his vital role as the Chief Executive Officer and President of the Company. He offers industry experience from global commercial, operational, and leadership perspectives. He has the ability and willingness to serve on the Board, and the correct fit to work in a collegial manner with the other directors.

Mr. Bronson served as Executive Vice President and Chief Financial Officer of PSS World Medical, Inc. from 2002 until it was acquired by McKesson Corp in 2013. Prior to that, he was Chief Financial Officer of Digineer, Inc. from 2001 to 2002 and of VWR Scientific Products from 1995 to 1999, when it was acquired by Merck KGaA. Mr. Bronson previously spent 15 years at Baxter Healthcare, Inc., where he held various senior financial executive positions. He was a director and a member of the Audit Committee of Labsco, Inc. until 2016 and was a director and Audit Committee Chair of AxelaCare, Inc. through November 2015. Mr. Bronson received his Master of Science in Management Studies from Northwestern University’s Kellogg School of Business and his Bachelor of Science in Accounting from California State University, Fullerton. The Board of Directors has determined that Mr. Bronson is independent within the meaning of the rules of the New York Stock Exchange, and that he is an audit committee financial expert within the meaning of the rules of the Securities and Exchange Commission.

Mr. Bronson’s qualifications for election to CONMED’s Board include substantial experience as a Chief Financial Officer generally, and specifically in the healthcare industry, as well as financial and accounting expertise acquired through prior positions. His exposure to, and familiarity with, healthcare services matters provide an important perspective to the Board. He has the ability and willingness to serve on the Board, and the correct fit to work in a collegial manner with the other directors.

Mr. Concannon served as President and CEO and as a member of the Board of Directors of Haemonetics Corporation, a publicly traded company (NYSE: HAE) from April 2009 to October 2015. He joined Haemonetics in 2003 and served in various roles to include the President, Global Markets in 2006 and the Chief Operating Officer from 2007 to 2009. Prior to joining Haemonetics, Mr. Concannon was the President, Northeast Region, for Cardinal Health (NYSE: CAH) Medical Products and Services where he was employed from 1998 to 2003. Prior to this, he was employed by American Hospital Supply Corporation, Baxter Healthcare Corp and Allegiance Healthcare in a series of sales and operations management positions of increasing responsibility. He has served in leadership roles within the healthcare industry for more than 30 years. Mr. Concannon has been a member of the Board of Directors of Hivers and Strivers, an investment fund, since September 2020, and a member of the Board of Directors of VetAccel since November 2019. Mr. Concannon was also a member of the Board of Directors of South Shore Health and was Vice-Chair from January 2017 to December 2019. He was also a member of the Board of Directors of My Brother’s Keeper beginning in January 2010, serving as the Chair of the Board from September 2011 to December 2021, and served as a member of the Board of Aegle Health Partners from October 2021 to May 2023. Additionally, Mr. Concannon was appointed as the Civilian Aide to the Secretary of the Army for Massachusetts in 2017, in which he served until 2024. Mr. Concannon is a graduate of the United States Military Academy at West Point. The Board of Directors has determined that Mr. Concannon is independent within the meaning of the rules of the New York Stock Exchange.

Mr. Concannon’s qualifications for election to CONMED’s Board include his experience as a former CEO and director of a publicly-traded medical device company, and the former president of a distribution company. Mr. Concannon offers industry experience from a sales and marketing perspective. He has the ability and willingness to serve on the Board, and the correct fit to work in a collegial manner with the other directors.

Ms. Goldberg Aronson has managed global health care businesses ranging in size from $500 million to $1.0 billion. She was the Executive Vice President and President of Global Healthcare for Ecolab, Inc. (NYSE: ECL) from 2012 to 2015, having previously served as the Senior Vice President and President – North America for Hill-Rom Holdings, Inc. (NYSE: HRC) from 2010 to 2012. Prior to that, Ms. Goldberg Aronson was the Senior Vice President and Chief Talent Officer for Medtronic, Inc. (NYSE: MDT), having held various prior general management positions within Medtronic, both in the U.S. and internationally. Ms. Goldberg Aronson holds a Bachelor of Arts in Economics from Wellesley College, and a Master of Business Administration from Harvard Business School. Ms. Goldberg Aronson served as Chair of the Board October 2024 to May 2025, and previously served as Lead Independent Director from May 2020 to October 2024. Ms. Goldberg Aronson also served on the Board of Directors of Methode Electronics, Inc. (NYSE: MEI) through September 2019, Clinical Innovations, LLC through December 2019, and Cardiovascular Systems, Inc. (NASDAQ: CSII) through April 2023. Ms. Goldberg Aronson also served as a director of Beta Bionics, Inc. from February 2020 to October 2022, having served as interim Chief Executive Officer from February 2022 to August 2022. Ms. Goldberg Aronson joined the Board of Bright Uro, Inc. in April 2024 and the Board of OmCare Inc. in November 2024. The Board of Directors has determined that Ms. Goldberg Aronson is independent within the meaning of the rules of the New York Stock Exchange.

Ms. Goldberg Aronson’s qualifications for election to CONMED’s Board include her extensive experience in the global healthcare markets, including leadership roles within medical device companies, and her experience in marketing and talent development. The Board strongly believes that the Board and Company benefits from the perspectives that Ms. Goldberg Aronson brings to the Board and the Company from her business experience. She has the ability and willingness to serve on the Board, and the correct fit to work in a collegial manner with the other directors.

Mr. Farkas has spent more than 40 years at Bain & Company. Mr. Farkas became an Advisory Partner of Bain & Company in July 2015. Prior to this, Mr. Farkas was a Senior Partner at Bain & Company, served as the Global Co-Head of Bain’s Healthcare Practice, and advised leading medical technology and pharmaceutical companies in the United States, Europe, and Asia. He also advised academic medical centers and provider organizations in the United States. Mr. Farkas also advised chief executives and senior managers in a wide variety of industries on issues critical to long-term success, including strategy, mergers and acquisitions, and operational effectiveness. He has served as the Managing Director of Bain Canada and as the global leader of Bain & Company’s financial services practice. Prior to working at Bain, Mr. Farkas received a Bachelor of Arts from Princeton University and a Master of Business Administration from Harvard Business School. Mr. Farkas is currently on the Boards of the John A. Hartford Foundation, Medzown, Inc., Wellist, LLC, and United Bridge Partners. He also serves as Chair of the Board of Medicinal Genomics Corporation. Previously, Mr. Farkas served on the Harvard Medical School Board from 2005 to 2017. The Board of Directors has determined that Mr. Farkas is independent within the meaning of the rules of the New York Stock Exchange.

Mr. Farkas’ qualifications for election to CONMED’s Board include his more than 40 years working in the healthcare and medical technology fields in the U.S. and around the world. Mr. Farkas is a highly respected leader, and he provides the Board with valuable strategic and governance perspectives, drawing on his vast experience inside and outside the healthcare industry. He has the ability and willingness to serve on the Board, and the correct fit to work in a collegial manner with the other directors.

Mr. Kaye has served as the Executive Vice President and Chief Financial Officer of Elevance Health (Mr. Kaye has served as the Executive Vice President and Chief Financial Officer of Elevance Health (“Elevance”) since November 2023. Prior to joining Elevance, he served as the Executive Vice President and Chief Financial Officer of Moody’s Corporation (“Moody’s”) from April 2021 to September 2023, with responsibility for all global finance activities across the company and as Senior Vice President and Chief Financial Officer from August 2018 to April 2021. Prior to Moody’s, he served as Senior Vice President and Head of Financial Planning and Analysis at Massachusetts Mutual Life Insurance Company (“MassMutual”) from February 2016 until July 2018, and Chief Financial Officer of MassMutual U.S. since July 2015. Prior to that, Mr. Kaye served as Chief Financial Officer and Senior Vice President, Retirement Solutions, at Voya Financial (formerly ING U.S.) from 2011 to 2015, and Mr. Kaye previously held various senior financial and risk reporting positions at ING U.S. and ING Group. Prior to that, Mr. Kaye worked in the investment banking division of Credit Suisse First Boston. Mr. Kaye has served as a Director on the Board of BCS Financial Corporation since May 2024. Mr. Kaye holds a Bachelor’s in Actuarial Science and Statistics from the University of Pennsylvania and a Master of Business Administration in Finance from The Wharton School at the University of Pennsylvania. The Board of Directors has determined that Mr. Kaye is independent within the meaning of the rules of the New York Stock Exchange, and that he is an audit committee financial expert within the meaning of the rules of the Securities and Exchange Commission.

Mr. Kaye’s qualifications for election to CONMED’s Board include his extensive experience as a Chief Financial Officer generally, and in the healthcare industry, as well as his financial and accounting expertise acquired through his prior positions. His exposure to, and familiarity with, healthcare services matters provide an important perspective to the Board. Over the last five years, he has held senior roles overseeing strategic planning, operational efficiencies, and organizational growth initiatives. This background, combined with a strong emphasis on corporate governance, risk management, and financial oversight, equips him with the skills and insights needed to guide the Company’s future direction. He has the ability and willingness to serve on the Board, and he is an excellent fit to work collaboratively with the other directors.

Ms. Schwarzentraub held various roles at Caterpillar, Inc. (NYSE: CAT) from 1990 to 2020. Most recently, she was the Director and Divisional Chief Financial Officer for their Global Information Services Division from 2017 to 2020. Prior to this, she held roles including Director of Caterpillar’s Global Component Manufacturing and Supply Chain, Vice President of Caterpillar Logistics Services Inc., Director of Caterpillar’s Parts Distribution, and Director of Global Finance Transformation. Prior to these roles, Ms. Schwarzentraub held several positions of increasing responsibility within Caterpillar. Ms. Schwarzentraub received her Master of Business Administration and Bachelor of Science in Accounting from Bradley University. The Board of Directors has determined that Ms. Schwarzentraub is independent within the meaning of the rules of the New York Stock Exchange, and that she is an audit committee financial expert within the meaning of the rules of the Securities and Exchange Commission.

Ms. Schwarzentraub’s qualifications for appointment to CONMED’s Board include her extensive global experience in information technology and supply chain management, leading large organizations, and finance and accounting. The Board strongly believes that the Board and Company benefits from the perspectives that Ms. Schwarzentraub brings to the Board and the Company as a result of her business experience. She has the ability and willingness to serve on the Board, and the correct fit to work in a collegial manner with the other directors.

Executive Officers

Mr. Epinette was promoted to Vice President and General Manager, International in October 2020. He joined the Company October in 2015 as Vice President and General Manager EMEA (Europe, Middle East, Africa). Prior to joining CONMED, Mr. Epinette served as Senior Vice President International Commercial Operations at Tornier from 2008 to 2015. Prior to this, he held various leadership roles at Stryker Corporation (NYSE: SYK), where he contributed to the MedSurg and Orthopaedic divisions in France, the United States, and Switzerland from 1993 to December 2008. Mr. Epinette holds a Master’s Degree in Health Economics from Sciences Po, Paris, a Master’s Degree in International Business from Paris University XII, and a Bachelor of Arts from EBMS Barcelona. Additionally, he has completed executive courses in Finance and Marketing at INSEAD.

Mr. Ferrell was promoted to Executive Vice President, Human Resources, in December 2022. Prior to this, Mr. Ferrell served as Vice President, Human Resources, International and Global Orthopedics from 2021 to 2022, and Vice President, Human Resources, International from 2015 to 2021. Prior to joining the Company, Mr. Ferrell worked for Stryker Corporation (NYSE: SYK) from 1994 to 2015, where he was Vice President, Human Resources, for the Orthopedics Group from 2012 to 2015, after previously serving as Vice President, Human Resources and Organizational Development, Europe, from 2009 to 2012. Mr. Ferrell serves on the Board of LECMPA, a non-profit insurer for transportation workers. Mr. Ferrell has a Bachelor of Arts in Psychology from Oakland University, and a Master of Arts in Labor and Industrial Relations from Michigan State University.

Ms. Foust joined the Company in November 2024 as Executive Vice President, General Counsel and Corporate Secretary. Prior to joining the Company, Ms. Foust held the role of Senior Vice President, Deputy General Counsel at Cardinal Health (NYSE: CAH) since 2021. Prior to this role, Ms. Foust held several roles across legal and compliance with increasing responsibility at Cardinal Health since 2009. Before Cardinal Health, Ms. Foust held various legal roles supporting the U.S. and International nutrition business of Abbott Laboratories (NYSE: ABT). Ms. Foust started her career in private practice at Bailey Cavalieri, LLC, where she focused on banking and financing transactions. She received her undergraduate degree and law degree from The Ohio State University.

Mr. Garner joined the Company as Executive Vice President and Chief Financial Officer in January 2018. Prior to joining CONMED, he was Vice President Investor Relations at C.R. Bard, Inc. from 2011 to December 2017. Mr. Garner’s previous positions at C.R. Bard, Inc. included Vice President, Controller (Division Chief Financial Officer) for its Medical division from 2007 to 2011, Director of Financial Reporting from 2005 to 2007, and Controller of the Reynosa Operations from 2003 to 2005. Before working at C.R. Bard, Inc., Mr. Garner was the acting Chief Financial Officer and Controller at Echopass Corporation (now Genesys Corporation) from 2000 to 2003, the Controller and Value Planning Manager at Futura Industries, Corp. from 1997 to 2000, Accounting Manager at Excel Communications in 1997, and Accounting Coordinator at Verizon from 1995 to 1996. Mr. Garner began his career at Arthur Andersen LLP, where he was a senior auditor from 1992 to 1995. Mr. Garner holds a Master of Business Administration from the University of Texas – Rio Grande Valley, and a Bachelor of Science in Accounting from Brigham Young University. Mr. Garner is also a Certified Public Accountant.

Mr. Glaze joined the Company as Chief Information Officer in November 2023. Prior to joining CONMED, he was IT Vice President, North America at Teva Pharmaceuticals (NYSE: TEVA) from August 2020 to November 2023. Prior to working at Teva Pharmaceuticals, Mr. Glaze was the IT Vice President, North America for SUN Pharmaceuticals (NSE: SUNPHARMA) from 2016 to 2020, IT Vice President at Ikaria (now Mallinckrodt Pharmaceuticals, NYSE: MNK) from 2013 to 2016, Sr. IT Director at Hospira (now Pfizer, NYSE: PFE) from 2010 to 2013, and held various positions at Johnson and Johnson (NYSE: JNJ) from 2002 to 2010. Mr. Glaze began his career in consulting, working at Andersen Consulting (now Accenture), Price Waterhouse Coopers, IBM, and KPMG Consulting (now BearingPoint) from 1991 to 2002. Mr. Glaze holds a Master of Business Administration from the Stern School of Business at New York University and a Bachelor of Science from Princeton University.

Mr. Lalomia was promoted to the role of Executive Vice President, Regulatory Affairs, Quality Assurance, Clinical Affairs, and Commercial Operations in March 2025. Prior to this, he assumed the role of Vice President, Quality Assurance, Regulatory Affairs, Customer Experience, and Logistics in May 2023. Prior to this, Mr. Lalomia joined CONMED as the Vice President, Quality Assurance and Regulatory Affairs in 2019. Prior to joining the Company, Mr. Lalomia worked for Stryker Corporation (NYSE: SYK) from 1996 to 2019, most recently as the Vice President, Quality Assurance and Facilities Management of the Stryker Instruments Division from 2014 to 2019. Mr. Lalomia holds a Master of Business Administration from the University of Notre Dame and a Bachelor of Science in Mechanical Engineering from Western Michigan University.

Mr. Moller joined CONMED as Vice President, Corporate Controller in February 2025. Prior to joining the Company, he was employed by Smith & Nephew from May 2019 to December 2024, where he most recently served as Global Controller and CFO Asia-Pacific. Prior to Smith & Nephew, Mr. Moller held various finance and audit positions at Stanley Black & Decker, Inc. and Coca-Cola Company. Prior to this, he was an auditor with Ernst & Young LLP. Mr. Moller is a Certified Public Accountant and graduated with a Bachelor of Science in Business Administration from the College of Charleston and a Master of International Business Studies from the University of South Carolina.

Ms. Pelletier was promoted to Treasurer and Vice President, Tax in April 2015. She joined the Company in 2005 in the role of Tax Director. Prior to joining the Company, she worked for PricewaterhouseCoopers, where she most recently served as a Tax Senior Manager. Ms. Pelletier is a Certified Public Accountant and graduated with a Bachelor of Science in Accounting from Le Moyne College.

Mr. Schabacker joined CONMED as Vice President and General Manager, U.S. Advanced Surgical in April 2025. Prior to joining the Company, he was employed by Becton Dickinson and Co (NYSE: BDX) from 2011 through April 2025 in multiple leadership roles, most recently in the position of Vice President and General Manager, Pharmacy Automation and prior to that as Vice President and General Manager, Advanced Drug Delivery Solutions and Head of Global Business Development for Pharmaceutical Systems. Mr. Schabacker also led Becton Dickinson’s International Infusion business from 2020 to 2022 while based in Eysins, Switzerland. Prior to his employment at Becton Dickinson, Mr. Schabacker was a Management Consultant at McKinsey & Company. Prior to this, he was a practicing pharmacist. Mr. Schabacker graduated with a Doctor of Pharmacy from Rutgers University School of Pharmacy, and a Master of Business Administration from Columbia Business School of Columbia University.

Mr. Shagory joined the Company as Executive Vice President, Strategy and Corporate Development in May 2015. Mr. Shagory has more than 25 years of experience in healthcare venture investing and mergers and acquisitions through his previous venture capital, investment banking, and corporate roles. Prior to joining the Company, Mr. Shagory led the strategy and business development efforts for Cardinal Health’s (NYSE: CAH) Medical Products Group within the Medical Segment from 2013 to 2015, where he played a key role in Cardinal Health’s entry into interventional cardiovascular and the advanced wound care categories. Prior to that, Mr. Shagory led the healthcare and life sciences investment effort at Baird Venture Partners from 2004 to 2013, focusing on medical technology and research tools and diagnostics. Mr. Shagory earned a Master of Business Administration from Dartmouth’s Tuck School of Business and a Bachelor of Science in Finance from Miami University in Oxford, Ohio.

製品情報

診療科別

教育・セミナー

サービス&サポート

Why CONMED

コーポレートガバナンス

Board of Directors

Executive Officers

製品情報

診療科別

教育・セミナー

サービス&サポート

Why CONMED

コーポレートガバナンス

Board of Directors

LaVerne Council Chair of the Board

PATRICK J. BEYER President and Chief Executive Officer

DAVID BRONSON Director

BRIAN P. CONCANNON Director

Martha Goldberg Aronson Director

Charles M. Farkas Director

MARK KAYE Director

BARBARA J. SCHWARZENTRAUB Director

Executive Officers

PATRICK J. BEYER President and Chief Executive Officer

STEPHAN EPINETTE Vice President and General Manager, International

JOHN FERRELL Executive Vice President, Human Resources

Heidi Foust Executive Vice President, General Counsel and Corporate Secretary

TODD W. GARNER Executive Vice President, Finance and Chief Financial Officer

RICHARD GLAZE Chief Information Officer

BRENT LALOMIA Executive Vice President, Regulatory Affairs, Quality Assurance, Clinical Affairs, and Commercial Operations

ANDREW MOLLER Vice President, Corporate Controller

JOHONNA PELLETIER Treasurer and Vice President, Tax

MATTHEW SCHABACKER Vice President and General Manager, U.S. Advanced Surgical

PETER K. SHAGORY Executive Vice President, Strategy and Corporate Development